Ginkgo Bioworks (DNA) Projected to Post Earnings on Thursday

Key Points

• Ginkgo Bioworks is projected to report its Q2 2025 earnings on August 7th, with analysts predicting a loss of ($1.44) per share and revenue of $41.60 million.
• The company had previously reported a larger loss of ($1.58) EPS in its last quarter, missing expectations and showing a negative return on equity of 52.35%.
• Institutional investors control 78.63% of Ginkgo Bioworks' shares, with significant stake increases from firms like Goldman Sachs and AQR Capital Management in the first quarter.

Ginkgo Bioworks (NYSE:DNA - Get Free Report) is expected to post its Q2 2025 quarterly earnings results after the market closes on Thursday, August 7th. Analysts expect Ginkgo Bioworks to post earnings of ($1.44) per share and revenue of $41.60 million for the quarter. Ginkgo Bioworks has set its FY 2025 guidance at EPS.

Ginkgo Bioworks (NYSE:DNA - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.35). Ginkgo Bioworks had a negative return on equity of 52.35% and a negative net margin of 198.84%. The company had revenue of $48.32 million during the quarter, compared to analysts' expectations of $38.70 million. On average, analysts expect Ginkgo Bioworks to post $-10 EPS for the current fiscal year and $-6 EPS for the next fiscal year.

Ginkgo Bioworks Stock Performance

DNA stock opened at $12.18 on Friday. The firm has a 50 day moving average price of $10.05 and a 200-day moving average price of $9.35. Ginkgo Bioworks has a 52-week low of $5.00 and a 52-week high of $16.85. The firm has a market capitalization of $712.90 million, a price-to-earnings ratio of -1.33 and a beta of 1.50.

Institutional Investors Weigh In On Ginkgo Bioworks

A number of hedge funds have recently modified their holdings of the business. Acadian Asset Management LLC bought a new position in Ginkgo Bioworks in the 1st quarter worth $120,000. Goldman Sachs Group Inc. lifted its stake in Ginkgo Bioworks by 25.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 686,767 shares of the company's stock worth $3,915,000 after purchasing an additional 139,126 shares in the last quarter. Millennium Management LLC lifted its stake in Ginkgo Bioworks by 113.1% in the 1st quarter. Millennium Management LLC now owns 1,427,600 shares of the company's stock worth $8,137,000 after purchasing an additional 757,535 shares in the last quarter. Finally, AQR Capital Management LLC lifted its stake in Ginkgo Bioworks by 322.6% in the 1st quarter. AQR Capital Management LLC now owns 158,939 shares of the company's stock worth $906,000 after purchasing an additional 121,326 shares in the last quarter. Institutional investors own 78.63% of the company's stock.

Ginkgo Bioworks Company Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.